Digest Network Come funziona
Network
/
Società
Ra
Non verificato

Radiant Biotherapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniOncologiaSalute

6 comunicati stampa

Guarda tutti i comunicati
05/11/2025
Scienza
HIV, AIDS e malattie autoimmuni
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Eventi
Industria
Radiant Biotherapeutics to Present New Data from Lead Oncology Program at SITC 2025 Annual Meeting
Fonte
Radiant Biotherapeutics
Emittente
Business Wire
1.00
0
04/11/2025
Scienza
HIV, AIDS e malattie autoimmuni
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Eventi
Industria
Radiant Biotherapeutics to Present New Data from Lead Oncology Program at SITC 2025 Annual Meeting
Fonte
Radiant Biotherapeutics
Emittente
Business Wire
1.00
0
03/10/2025
Eventi
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Radiant Biotherapeutics to Present Next-Generation Multabody™ Approach for Cancer Immunotherapy at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Fonte
Radiant Biotherapeutics
Emittente
Business Wire
1.00
0
09/07/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Radiant Biotherapeutics Appoints Deborah Geraghty, Ph.D., as President and Chief Executive Officer
Fonte
Radiant Biotherapeutics
Emittente
Business Wire
1.00
0
25/04/2025
Eventi
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Scienza
Farmaceutica
Biotecnologia
Radiant Biotherapeutics Announces Poster Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting
Fonte
Radiant Biotherapeutics
Emittente
Business Wire
1.00
0
11/09/2024
Biotecnologia
Associazioni/Professionisti
Salute
Farmaceutica
Oncologia
Scienza
HIV, AIDS e malattie autoimmuni
Finanza
Radiant Bio Closes $35 Million Series A Financing to Advance Therapeutic Pipeline with Its Proprietary Multabody™ Platform
Fonte
Radiant Biotherapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0